Audentes Therapeutics, Inc.
DelistedCIK 1628738fmd_08B00Z6RG81NSGS82G7F8FZK9ZManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2014 to Sep 30, 2019, 20 periods
Latest annual · FY2018
Millions- Operating income
- (134)
- Net income
- (129)
- Free cash flow
- (120)
Latest quarter · Q3 FY2019
Millions- Operating income
- (48)
- Net income
- (46)
- Free cash flow
- (40)
Audentes Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2018 | FY2017 | Change | Source |
|---|---|---|---|---|
| Operating income | -$134.4 million | -$93.2 million | 10-K 2019-03-01 · proof | |
| Net income | -$128.8 million | -$90.2 million | 10-K 2019-03-01 · proof | |
| Cash from operating activities | -$108 million | -$84.6 million | 10-K 2019-03-01 · proof | |
| Free cash flow | -$119.6 million | -$92.1 million | 10-K 2019-03-01 · proof | |
| Total assets | $472.6 million | $178.7 million | +164.5% | 10-K 2019-03-01 · proof |
| Total liabilities | $29.8 million | $22.1 million | +35.1% | 10-K 2019-03-01 · proof |
| Cash and cash equivalents | $144.3 million | $39 million | +270.4% | 10-K 2019-03-01 · proof |
- What was Audentes Therapeutics, Inc.'s operating income in fiscal 2018?
- Audentes Therapeutics, Inc. reported operating income of -$134.4 million for fiscal 2018 (the year ended Dec 31, 2018), against -$93.2 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2019. SEC
- What was Audentes Therapeutics, Inc.'s net income in fiscal 2018?
- Audentes Therapeutics, Inc. reported net income of -$128.8 million for fiscal 2018 (the year ended Dec 31, 2018), against -$90.2 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2019. SEC
- What was Audentes Therapeutics, Inc.'s cash from operating activities in fiscal 2018?
- Audentes Therapeutics, Inc. reported cash from operating activities of -$108 million for fiscal 2018 (the year ended Dec 31, 2018), against -$84.6 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2019. SEC
- What was Audentes Therapeutics, Inc.'s free cash flow in fiscal 2018?
- Audentes Therapeutics, Inc. reported free cash flow of -$119.6 million for fiscal 2018 (the year ended Dec 31, 2018), against -$92.1 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2019. SEC
- What are Audentes Therapeutics, Inc.'s total assets?
- As of Dec 31, 2018, Audentes Therapeutics, Inc. reported total assets of $472.6 million, against $178.7 million a year earlier (+164.5%). Source: the 10-K filed with the SEC on Mar 1, 2019. SEC
- What are Audentes Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2018, Audentes Therapeutics, Inc. reported total liabilities of $29.8 million, against $22.1 million a year earlier (+35.1%). Source: the 10-K filed with the SEC on Mar 1, 2019. SEC
- What are Audentes Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2018, Audentes Therapeutics, Inc. reported cash and cash equivalents of $144.3 million, against $39 million a year earlier (+270.4%). Source: the 10-K filed with the SEC on Mar 1, 2019. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1628738&period_type=annual&limit=5"Information only, not investment advice.